R. Michael Lawrence

Bristol-Myers Squibb (United States)

Papers

1

Total Citations

11

H-Index

1

About

R. Michael Lawrence is a biochemist specializing in metabolic disease research, with a focus on lipid metabolism and enzyme inhibition. His major contributions center on the development of innovative cellular assays to study monoacylglycerol acyltransferase 2 (MGAT2), a key enzyme in dietary fat absorption and triglyceride synthesis. In his most-cited work (2015, 11 citations), Lawrence pioneered a cell-based assay for profiling MGAT2 inhibitors, replacing traditional low-throughput, radiolabeled methods with a stable isotope-labeled substrate and high-resolution LC/MS. This approach enabled more accurate, scalable screening of potential therapeutic compounds for obesity and metabolic disorders. By constructing recombinant human MGAT2-expressing cell lines from murine enteroendocrine cells, he provided a physiologically relevant platform for drug discovery. Though his citation count reflects a focused, emerging impact, Lawrence’s work represents a critical methodological advance in metabolic pharmacology, bridging cellular biology and analytical chemistry. His assay design has implications for developing targeted therapies against dyslipidemia and type 2 diabetes, marking him as a contributor to precision tools in metabolic research.

Research Focus

Key Achievements

1
H-Index
1
Papers
11
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
Cell-based assay of MGAT2-driven diacylglycerol synthesis for profiling inhibitors: use of a stable isotope-labeled substrate and high-resolution LC/MS
11 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Bristol-Myers Squibb (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago